Skip to content
2000
Volume 32, Issue 8
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Recombinant proteins, which are produced using recombinant DNA technology, have transformed the domains of biotechnology and biomedicine by allowing the production of proteins that are often expensive or difficult to obtain from natural sources. More than 130 recombinant proteins are currently in clinical use by the US FDA, demonstrating the importance of these proteins in both research and therapeutic applications. Bacterial, yeast, mammalian cell cultures, and hybridoma technology are examples of recombinant protein production systems that have enabled the large-scale production of therapeutic proteins, including monoclonal antibodies, which are now essential tools in disease treatment. From their origins with human insulin in the 1980s to the most recent developments in third-generation proteins, this brief review examines the development of recombinant protein therapies. The first generation concentrated on natural structures; the second generation focused on enhancing safety, pharmacokinetics, and specificity; and the third generation is ready to present innovative formulations and delivery systems. This review also covers the use of recombinant proteins in cancer treatment, different protein production systems, and design techniques that keep improving the safety and effectiveness profiles of protein therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665387985250710041016
2025-08-01
2026-02-26

  • From This Site

    /content/journals/ppl/10.2174/0109298665387985250710041016
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GrillbergerL. KreilT.R. NasrS. ReiterM. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.Biotechnol. J.20094218620110.1002/biot.20080024119226552
     [Google Scholar]
  2. DavamiF. BarkhordariF. AlebouyehM. AdeliA. MahboudiF. Combined TGE-SGE expression of novel PAI-1-resistant t-PA in CHO DG44 cells using orbitally shaking disposable bioreactors.J. Microbiol. Biotechnol.201121121299130510.4014/jmb.1106.0506022210617
     [Google Scholar]
  3. MaJ.K.C. DrakeP.M.W. ChristouP. The production of recombinant pharmaceutical proteins in plants.Nat. Rev. Genet.200341079480510.1038/nrg117714526375
     [Google Scholar]
  4. Ojima-KatoT. Advances in recombinant protein production in microorganisms and functional peptide tags.Biosci. Biotechnol. Biochem.202489111010.1093/bbb/zbae14739479788
     [Google Scholar]
  5. LicoC. ChenQ. SantiL. Viral vectors for production of recombinant proteins in plants.J. Cell. Physiol.2008216236637710.1002/jcp.2142318330886
     [Google Scholar]
  6. KhanS. UllahM.W. SiddiqueR. NabiG. MananS. YousafM. HouH. Role of recombinant DNA technology to improve life.Int. J. Genomics2016201611410.1155/2016/240595428053975
     [Google Scholar]
  7. AlyasE.J. RafiqA. AmirH. KhanS.U. SultanaT. AliA. HameedA. AhmadI. KazmiA. SajidT. AhmadA. Human insulin: History, recent advances, and expression systems for mass production.Biomed. Res. Ther.2021894540456110.15419/bmrat.v8i9.692
     [Google Scholar]
  8. Sanchez-GarciaL. MartínL. ManguesR. Ferrer-MirallesN. VázquezE. VillaverdeA. Recombinant pharmaceuticals from microbial cells: A 2015 update.Microb. Cell Fact.20161513310.1186/s12934‑016‑0437‑326861699
     [Google Scholar]
  9. Ferrer-MirallesN. Domingo-EspínJ. CorcheroJ.L. VázquezE. VillaverdeA. Microbial factories for recombinant pharmaceuticals.Microb. Cell Fact.2009811710.1186/1475‑2859‑8‑1719317892
     [Google Scholar]
  10. GoffS.P. ShenkT. Paul Berg: Recombinant DNA trailblazer.Proc. Natl. Acad. Sci. USA202312047231819612010.1073/pnas.2318196120
     [Google Scholar]
  11. MustafaA. NasirM.F. AzizI. HussainT. A revolution by recombinant DNA technology to improve the quality of life.Biom. Lett.202171122510.47262/BL/7.1.20201223
     [Google Scholar]
  12. MitraS. TomarP.C. Hybridoma technology; advancements, clinical significance, and future aspects.J. Genet. Eng. Biotechnol.202119115910.1186/s43141‑021‑00264‑634661773
     [Google Scholar]
  13. VargasonA.M. AnselmoA.C. MitragotriS. The evolution of commercial drug delivery technologies.Nat. Biomed. Eng.20215995196710.1038/s41551‑021‑00698‑w33795852
     [Google Scholar]
  14. ViegasC. SeckF. FonteP. An insight on lipid nanoparticles for therapeutic proteins delivery.J. Drug Deliv. Sci. Technol.20227710383910.1016/j.jddst.2022.103839
     [Google Scholar]
  15. YinL. YuviencoC. MontclareJ.K. Protein based therapeutic delivery agents: Contemporary developments and challenges.Biomaterials20171349111610.1016/j.biomaterials.2017.04.03628458031
     [Google Scholar]
  16. AlexanderE. LeongK.W. Discovery of nanobodies: A comprehensive review of their applications and potential over the past five years.J. Nanobiotechnol.202422166110.1186/s12951‑024‑02900‑y39455963
     [Google Scholar]
  17. TripathiN.K. ShrivastavaA. Recent developments in bioprocessing of recombinant proteins: Expression hosts and process development.Front. Bioeng. Biotechnol.2019742010.3389/fbioe.2019.0042031921823
     [Google Scholar]
  18. FrancisD.M. PageR. Strategies to optimize protein expression in E. coli.Curr. Protoc. Protein Sci.2010515.24.15.24.2910.1002/0471140864.ps0524s6120814932
     [Google Scholar]
  19. NiaziS.K. MagoolaM. Advances in Escherichia coli-based therapeutic protein expression: Mammalian conversion, continuous manufacturing, and cell-free production.Biologics20233438040110.3390/biologics3040021
     [Google Scholar]
  20. PouresmaeilM. Azizi-DargahlouS. Factors involved in heterologous expression of proteins in E. coli host.Arch. Microbiol.2023205521210.1007/s00203‑023‑03541‑937120438
     [Google Scholar]
  21. DysonM.R. ShadboltS.P. VincentK.J. PereraR.L. McCaffertyJ. Production of soluble mammalian proteins in Escherichia coli: Identification of protein features that correlate with successful expression.BMC Biotechnol.2004413210.1186/1472‑6750‑4‑3215598350
     [Google Scholar]
  22. ZhangL. LinX. WangT. GuoW. LuY. Development and comparison of cell-free protein synthesis systems derived from typical bacterial chassis.Bioresour. Bioprocess.2021815810.1186/s40643‑021‑00413‑234249606
     [Google Scholar]
  23. SaibilH. Chaperone machines for protein folding, unfolding and disaggregation.Nat. Rev. Mol. Cell Biol.2013141063064210.1038/nrm365824026055
     [Google Scholar]
  24. KolajO. SpadaS. RobinS. WallJ.G. Use of folding modulators to improve heterologous protein production in Escherichia coli.Microb. Cell Fact.200981910.1186/1475‑2859‑8‑919173718
     [Google Scholar]
  25. LiberekK. LewandowskaA. ZiętkiewiczS. Chaperones in control of protein disaggregation.EMBO J.200827232833510.1038/sj.emboj.760197018216875
     [Google Scholar]
  26. KarlaftisV. PereraS. MonagleP. IgnjatovicV. Importance of post-translational modifications on the function of key haemostatic proteins.Blood Coagul. Fibrinolysis20162711410.1097/MBC.000000000000030126484638
     [Google Scholar]
  27. ZhongQ. XiaoX. QiuY. XuZ. ChenC. ChongB. ZhaoX. HaiS. LiS. AnZ. DaiL. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.MedComm20234326110.1002/mco2.26137143582
     [Google Scholar]
  28. BurnettM.J.B. BurnettA.C. Therapeutic recombinant protein production in plants: Challenges and opportunities.Plants People Planet20202212113210.1002/ppp3.10073
     [Google Scholar]
  29. SookhooJ.R.V. SchiffmanZ. AmbagalaA. KobasaD. PardeeK. BabiukS. Protein expression platforms and the challenges of viral antigen production.Vaccines20241212134410.3390/vaccines1212134439772006
     [Google Scholar]
  30. LeeY.J. JeongK.J. Challenges to production of antibodies in bacteria and yeast.J. Biosci. Bioeng.2015120548349010.1016/j.jbiosc.2015.03.00925912450
     [Google Scholar]
  31. SchindlerD. Genetic engineering and synthetic genomics in yeast to understand life and boost biotechnology.Bioengineering20207413710.3390/bioengineering704013733138080
     [Google Scholar]
  32. YangP. CondrichA. LuL. ScrantonS. HebnerC. SheykhhasanM. AliM.A. Genetic engineering in bacteria, fungi, and oomycetes, taking advantage of CRISPR.DNA20244442745410.3390/dna4040030
     [Google Scholar]
  33. BoodhooK.V.K. FlickingerM.C. WoodleyJ.M. EmanuelssonE.A.C. Bioprocess intensification: A route to efficient and sustainable biocatalytic transformations for the future.Chem. Eng. Process.202217210879310.1016/j.cep.2022.108793
     [Google Scholar]
  34. GaoM.J. ZhengZ.Y. WuJ.R. DongS.J. LiZ. JinH. ZhanX.B. LinC.C. Improvement of specific growth rate of Pichia pastoris for effective porcine interferon-α production with an on-line model-based glycerol feeding strategy.Appl. Microbiol. Biotechnol.20129341437144510.1007/s00253‑011‑3605‑821983708
     [Google Scholar]
  35. KouT.C. FanL. ZhouY. YeZ.Y. ZhaoL. TanW.S. Increasing the productivity of TNFR-Fc in GS-CHO cells at reduced culture temperatures.Biotechnol. Bioprocess Eng.; BBE201116113614310.1007/s12257‑010‑0157‑1
     [Google Scholar]
  36. HillerE. OffM. HermannA. VahidinasabM. Benatto PerinoE.H. LilgeL. HausmannR. The influence of growth rate-controlling feeding strategy on the surfactin production in Bacillus subtilis bioreactor processes.Microb. Cell Fact.202423126010.1186/s12934‑024‑02531‑w39343903
     [Google Scholar]
  37. DavidF. DavisA.M. GossingM. HayesM.A. RomeroE. ScottL.H. WigglesworthM.J. A perspective on synthetic biology in drug discovery and development—current impact and future opportunities.SLAS Discov.202126558160310.1177/2472555221100066933834873
     [Google Scholar]
  38. ChenL. LiQ. NasifK.F.A. XieY. DengB. NiuS. PouriyehS. DaiZ. ChenJ. XieC.Y. AI-driven deep learning techniques in protein structure prediction.Int. J. Mol. Sci.20242515842610.3390/ijms2515842639125995
     [Google Scholar]
  39. JeongS.H. LeeH.J. LeeS.J. Recent advances in CRISPR-Cas technologies for synthetic biology.J. Microbiol.2023611133610.1007/s12275‑022‑00005‑536723794
     [Google Scholar]
  40. PatraJ.K. DasG. FracetoL.F. CamposE.V.R. Rodriguez-TorresM.P. Acosta-TorresL.S. Diaz-TorresL.A. GrilloR. SwamyM.K. SharmaS. HabtemariamS. ShinH.S. Nano based drug delivery systems: Recent developments and future prospects.J. Nanobiotechnol.20181617110.1186/s12951‑018‑0392‑830231877
     [Google Scholar]
  41. QinS. TangX. ChenY. ChenK. FanN. XiaoW. ZhengQ. LiG. TengY. WuM. SongX. mRNA-based therapeutics: Powerful and versatile tools to combat diseases.Signal Transduct. Target. Ther.20227116610.1038/s41392‑022‑01007‑w35597779
     [Google Scholar]
  42. DuarteT. SpencerC. Personalized proteomics: The future of precision medicine.Proteomes2016442910.3390/proteomes404002927882306
     [Google Scholar]
  43. SonA. ParkJ. KimW. LeeW. YoonY. JiJ. KimH. Integrating computational design and experimental approaches for next-generation biologics.Biomolecules2024149107310.3390/biom1409107339334841
     [Google Scholar]
  44. KintzingJ.R. Filsinger InterranteM.V. CochranJ.R. Emerging strategies for developing next-generation protein therapeutics for cancer treatment.Trends Pharmacol. Sci.20163712993100810.1016/j.tips.2016.10.00527836202
     [Google Scholar]
  45. GifreL. ArísA. BachÀ. Garcia-FruitósE. Trends in recombinant protein use in animal production.Microb. Cell Fact.20171614010.1186/s12934‑017‑0654‑428259156
     [Google Scholar]
  46. WangL. WangN. ZhangW. ChengX. YanZ. ShaoG. WangX. WangR. FuC. Therapeutic peptides: Current applications and future directions.Signal Transduct. Target. Ther.2022714810.1038/s41392‑022‑00904‑435165272
     [Google Scholar]
  47. LandgrafW. Recombinant human insulins - Clinical efficacy and safety in diabetes therapy.Eur. Endocrinol.20161211210.17925/EE.2016.12.01.1229632581
     [Google Scholar]
  48. PhamP.V. Medical biotechnology: Techniques and applications.Omics Technologies and Bio-Engineering.Elsevier44946910.1016/B978‑0‑12‑804659‑3.00019‑1
     [Google Scholar]
  49. ChenJ. BorraS. HuangA. FanL. PollomR.D. HoodR.C. Treatment patterns and outcomes before and after humulin R U-500 initiation among us patients with type 2 diabetes previously prescribed ≤ 200 Units/day of U-100 insulin.Diabetes Ther.202213346547910.1007/s13300‑022‑01209‑z35190970
     [Google Scholar]
  50. WeiseK.L. NahataM.C. Growth hormone use in children with idiopathic short stature.Ann. Pharmacother.20043891460146810.1345/aph.1D54815266039
     [Google Scholar]
  51. LoftusJ. HeatleyR. WalshC. DimitriP. Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature.J. Pediatr. Endocrinol. Metab.201023653555110.1515/jpem.2010.09220662327
     [Google Scholar]
  52. BercuB.B. MurrayF.T. FrasierS.D. RudlinC. O’DeaL.S. BrentzelJ. Long-term therapy with recombinant human growth hormone (Saizen) in children with idiopathic and organic growth hormone deficiency.Endocrine2001151434910.1385/endo:15:1:04311572324
     [Google Scholar]
  53. CoutantR. Bosch MuñozJ. DumitrescuC.P. SchnabelD. SertC. PerrotV. DattaniM. Effectiveness and overall safety of NutropinAq® for growth hormone deficiency and other paediatric growth hormone disorders: Completion of the International cooperative growth study, NutropinAq® European Registry (iNCGS).Front. Endocrinol.20211267608310.3389/fendo.2021.67608334113318
     [Google Scholar]
  54. SpiegelR.J. Intron A (interferon alfa-2b): Clinical overview and future directions.Semin. Oncol.1986133 Suppl 2891013532338
     [Google Scholar]
  55. KleinschnitzC. NiemczykG. Rehberg-WeberK. WernsdörferC. Interferon Beta-1a (AVONEX®) as a treatment option for untreated patients with multiple sclerosis (AXIOM): A prospective, observational study.Int. J. Mol. Sci.2015167152711528610.3390/ijms16071527126154767
     [Google Scholar]
  56. GottesmanM.H. Friedman-UrevichS. Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 mg: Interferon dose escalation assessment of safety (IDEAS).Mult. Scler.200612327128010.1191/135248506ms1261oa16764339
     [Google Scholar]
  57. GlaspyJ. BukowskiR. SteinbergD. TaylorC. TchekmedyianS. Vadhan-RajS. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice.J. Clin. Oncol.19971531218123410.1200/JCO.1997.15.3.12189060566
     [Google Scholar]
  58. ErlichL. Use of EPOGEN for treatment of anemia associated with chronic renal failure.Crit. Care Nurs. Clin. North Am.19902110111310.1016/S0899‑5885(18)30847‑52357306
     [Google Scholar]
  59. BoogaertsM. OberhoffC. Ten Bokkel HuininkW. NowrousianM.R. HaywardC.R.W. BurgerH.U. Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: A meta-analysis.Anticancer Res.2006261B47948416739308
     [Google Scholar]
  60. GiangrandeP.L.F. Safety and efficacy of KOGENATE ® Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs).Haemophilia20028 Suppl 2192210.1046/j.1351‑8216.2001.00133.x11966848
     [Google Scholar]
  61. ShimaM. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.Ann. Hematol.202410382647265810.1007/s00277‑023‑05287‑237391649
     [Google Scholar]
  62. SwiechK. Picanço-CastroV. CovasD.T. Production of recombinant coagulation factors: Are humans the best host cells?Bioengineered20178546247010.1080/21655979.2017.127976728277160
     [Google Scholar]
  63. DuBuskeI. SchmidlinK. BernsteinJ.A. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment.Ann. Allergy Asthma Immunol.20211261969810.1016/j.anai.2020.08.02632866621
     [Google Scholar]
  64. PastoresG.M. Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.Biologics20071329130019707338
     [Google Scholar]
  65. AlekseevaL.A. Sen’kovaA.V. SounbuliK. SavinI.A. ZenkovaM.A. MironovaN.L. Pulmozyme ameliorates LPS-induced lung fibrosis but provokes residual inflammation by modulating cell-Free DNA composition and controlling neutrophil phenotype.Biomolecules202515229810.3390/biom1502029840001601
     [Google Scholar]
  66. JuluriK.R. SiuC. CassadayR.D. Asparaginase in the treatment of acute lymphoblastic leukemia in adults: Current evidence and place in therapy.Blood Lymphat. Cancer202212557910.2147/BLCTT.S34205235669980
     [Google Scholar]
  67. EzikeT.C. OkpalaU.S. OnojaU.L. NwikeC.P. EzeakoE.C. OkparaO.J. OkoroaforC.C. EzeS.C. KaluO.L. OdohE.C. NwadikeU.G. OgbodoJ.O. UmehB.U. OssaiE.C. NwangumaB.C. Advances in drug delivery systems, challenges and future directions.Heliyon2023961748810.1016/j.heliyon.2023.e1748837416680
     [Google Scholar]
  68. ShahD.K. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.J. Pharmacokinet. Pharmacodyn.201542555357110.1007/s10928‑015‑9447‑826373957
     [Google Scholar]
  69. EbrahimiS.B. SamantaD. Engineering protein-based therapeutics through structural and chemical design.Nat. Commun.2023141241110.1038/s41467‑023‑38039‑x37105998
     [Google Scholar]
  70. BashirS. FitaihiR. AbdelhakimH.E. Advances in formulation and manufacturing strategies for the delivery of therapeutic proteins and peptides in orally disintegrating dosage forms.Eur. J. Pharm. Sci.202318210637410.1016/j.ejps.2023.10637436623699
     [Google Scholar]
  71. AlRuthiaY. BahariO.H. AlghnamS. AlrumaihA.M. AsiriH. AlshammariM. AlhowimelM. Al-AbdulkarimH.A. Real-world impact of switching from insulin glargine (Lantus®) to Basaglar® and potential cost saving in a large public healthcare system in Saudi Arabia.Front. Public Health20221085272110.3389/fpubh.2022.85272135769787
     [Google Scholar]
  72. KeatingG.M. Insulin detemir: A review of its use in the management of diabetes mellitus.Drugs201272172255228710.2165/11470200‑000000000‑0000023110609
     [Google Scholar]
  73. OkikioluJ. WoodleyC. Cadman-DaviesL. O’SullivanJ. RadiaD. GarciaN.C. HarringtonP. KordastiS. AsirvathamS. SriskandarajahP. SaundersJ. SahaC. SanchezI. deLavalladeH. McLornanD.P. HarrisonC.N. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).Leuk. Res. Rep.20231910036010.1016/j.lrr.2022.10036036590864
     [Google Scholar]
  74. MatthewsS.J. McCoyC. Peginterferon alfa-2a: A review of approved and investigational uses.Clin. Ther.2004267991102510.1016/S0149‑2918(04)90173‑715336466
     [Google Scholar]
  75. PowellJ. Gurk-TurnerC. Darbepoetin alfa (Aranesp).Proc. Bayl. Univ. Med. Cent.200215333233510.1080/08998280.2002.1192786116333460
     [Google Scholar]
  76. BiganzoliL. UntchM. SkacelT. PicoJ.L. Neulasta (pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia.Semin. Oncol.2004313 Suppl 8273410.1053/j.seminoncol.2004.04.00215181606
     [Google Scholar]
  77. StieltjesN. AltisentC. AuerswaldG. NégrierC. PouzolP. ReynaudJ. Roussel-RobertV. SavidgeG.F. VillarA. SchulmanS. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: Clinical experience.Haemophilia200410545245810.1111/j.1365‑2516.2004.01013.x15357770
     [Google Scholar]
  78. YuC. WuC. YangY. JinH. Systemic monotherapy with acitretin for erythrodermic psoriasis: Results of a retrospective study of 81 patients.Ther. Adv. Chronic Dis.2023142040622323117841210.1177/2040622323117841237360416
     [Google Scholar]
  79. dos SantosJ.B.R. AlmeidaA.M. AcurcioF.A. de Oliveira JuniorH.A. KakehasiA.M. Guerra JuniorA.A. BennieM. GodmanB. AlvaresJ. Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System.J. Comp. Eff. Res.20165653954910.2217/cer‑2016‑002727641309
     [Google Scholar]
  80. BaurA.S. LutzM.B. SchiererS. BeltrameL. TheinerG. ZinserE. OstaleckiC. HeidkampG. HaendleI. ErdmannM. WiesingerM. LeisgangW. GrossS. PommerA.J. KämpgenE. DudziakD. SteinkassererA. CavalieriD. Schuler-ThurnerB. SchulerG. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.Blood2013122132185219410.1182/blood‑2012‑09‑45698823958949
     [Google Scholar]
  81. ZamanR. IslamR.A. IbnatN. OthmanI. ZainiA. LeeC.Y. ChowdhuryE.H. Current strategies in extending half-lives of therapeutic proteins.J. Control. Release201930117618910.1016/j.jconrel.2019.02.01630849445
     [Google Scholar]
  82. MukherjeeA.G. WanjariU.R. GopalakrishnanA.V. BraduP. BiswasA. GanesanR. RenuK. DeyA. VellingiriB. El AllaliA. AlsammanA.M. ZayedH. George Priya DossC. Evolving strategies and application of proteins and peptide therapeutics in cancer treatment.Biomed. Pharmacother.202316311483210.1016/j.biopha.2023.11483237150032
     [Google Scholar]
  83. WangC. GuoX. WangW. LiJ.X. WangT.Y. From cell clones to recombinant protein product heterogeneity in chinese hamster ovary cell systems.Int. J. Mol. Sci.2025263132410.3390/ijms2603132439941092
     [Google Scholar]
  84. BaiY. MercadéI.D. ElgendyR. LambiaseG. Peak-ChewS. FrancoC. WingettS.W. StevensT.J. GrassiL. HitchcockN. FerreiraC.S. HattonD. MillerE.A. MistryR.K. Identification of cellular signatures associated with chinese hamster ovary cell adaptation for secretion of antibodies.Comput. Struct. Biotechnol. J.202527173110.1016/j.csbj.2024.12.00639760073
     [Google Scholar]
  85. KimJ.Y. KimY.G. LeeG.M. CHO cells in biotechnology for production of recombinant proteins: Current state and further potential.Appl. Microbiol. Biotechnol.201293391793010.1007/s00253‑011‑3758‑522159888
     [Google Scholar]
  86. KarbalaeiM. RezaeeS.A. FarsianiH. Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins.J. Cell. Physiol.202023595867588110.1002/jcp.2958332057111
     [Google Scholar]
  87. KalkanA.K. PalazF. SofijaS. ElmousaN. LedezmaY. CachatE. Rios-SolisL. Improving recombinant protein production in CHO cells using the CRISPR-Cas system.Biotechnol. Adv.20236410811510.1016/j.biotechadv.2023.10811536758652
     [Google Scholar]
  88. Al-SalamaZ.T. ScottL.J. Lonoctocog Alfa: A review in Haemophilia A.Drugs201777151677168610.1007/s40265‑017‑0815‑028900904
     [Google Scholar]
  89. GermainD.P. LinhartA. Pegunigalsidase alfa: A novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease.Front. Genet.202415139528710.3389/fgene.2024.139528738680424
     [Google Scholar]
  90. FramptonJ.E. Efmoroctocog Alfa: A Review in Haemophilia A.Drugs202181172035204610.1007/s40265‑021‑01615‑w34743314
     [Google Scholar]
  91. EsaulenkoE.V. YakovlevA.A. VolkovG.A. SukhorukA.A. SurkovK.G. KruglyakovP.V. Diaz-MitomaF. Efficacy and safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B vaccine: Results of a phase 3 randomized clinical trial in the Russian federation.Clin. Infect. Dis.2021739e3333e333910.1093/cid/ciaa164933119068
     [Google Scholar]
  92. ValentinoL.A. RechtM. DipaolaJ. ShapiroA.D. PipeS.W. EwingN. UrgoJ. BullockT. SimmonsM. DeguzmanC. Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A.Haemophilia200915371872610.1111/j.1365‑2516.2008.01960.x19298383
     [Google Scholar]
  93. PetriniI. LucchesiM. PuppoG. ChellaA. Medical treatment of malignant pleural mesothelioma relapses.J. Thorac. Dis.201810Suppl 2S333S34110.21037/jtd.2017.10.15929507803
     [Google Scholar]
  94. BaskarR. LeeK.A. YeoR. YeohK.W. Cancer and radiation therapy: Current advances and future directions.Int. J. Med. Sci.20129319319910.7150/ijms.363522408567
     [Google Scholar]
  95. LiuB. ZhouH. TanL. SiuK.T.H. GuanX.Y. Exploring treatment options in cancer: Tumor treatment strategies.Signal Transduct. Target. Ther.20249117510.1038/s41392‑024‑01856‑739013849
     [Google Scholar]
  96. LiauwS.L. ConnellP.P. WeichselbaumR.R. New paradigms and future challenges in radiation oncology: An update of biological targets and technology.Sci. Transl. Med.20135173173sr210.1126/scitranslmed.300514823427246
     [Google Scholar]
  97. ZhouY. TaoL. QiuJ. XuJ. YangX. ZhangY. TianX. GuanX. CenX. ZhaoY. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct. Target. Ther.20249113210.1038/s41392‑024‑01823‑238763973
     [Google Scholar]
  98. BriukhovetskaD. DörrJ. EndresS. LibbyP. DinarelloC.A. KoboldS. Interleukins in cancer: From biology to therapy.Nat. Rev. Cancer202121848149910.1038/s41568‑021‑00363‑z34083781
     [Google Scholar]
  99. TsaoL.C. ForceJ. HartmanZ.C. Mechanisms of therapeutic antitumor monoclonal antibodies.Cancer Res.202181184641465110.1158/0008‑5472.CAN‑21‑110934145037
     [Google Scholar]
  100. ZhouW. LuX. TianF. LuoQ. ZhouW. YangS. LiW. YangY. ShiM. ZhouT. Vaccine therapies for prostate cancer: Current status and future outlook.Vaccines20241212138410.3390/vaccines1212138439772046
     [Google Scholar]
  101. CheungL.S. FuJ. KumarP. KumarA. UrbanowskiM.E. IhmsE.A. ParveenS. BullenC.K. PatrickG.J. HarrisonR. MurphyJ.R. PardollD.M. BishaiW.R. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti–PD-1 in melanoma.Proc. Natl. Acad. Sci. USA201911683100310510.1073/pnas.181508711630718426
     [Google Scholar]
  102. WhiteleyA.E. PriceT.T. CantelliG. SipkinsD.A. Leukaemia: A model metastatic disease.Nat. Rev. Cancer202121746147510.1038/s41568‑021‑00355‑z33953370
     [Google Scholar]
  103. LohcharoenkalW. WangL. ChenY.C. RojanasakulY. Protein nanoparticles as drug delivery carriers for cancer therapy.BioMed. Res. Int.2014201411210.1155/2014/18054924772414
     [Google Scholar]
  104. NaeimiR. BahmaniA. AfsharS. Investigating the role of peptides in effective therapies against cancer.Cancer Cell Int.202222113910.1186/s12935‑022‑02553‑735346211
     [Google Scholar]
  105. LamrabetO. DrancourtM. Genetic engineering of Mycobacterium tuberculosis: A review.Tuberculosis201292536537610.1016/j.tube.2012.06.00222789498
     [Google Scholar]
  106. BachmanJ. Site-directed mutagenesis.Methods in Enzymology.Elsevier201324124810.1016/B978‑0‑12‑418687‑3.00019‑7
     [Google Scholar]
  107. StrohlW.R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters.BioDrugs201529421523910.1007/s40259‑015‑0133‑626177629
     [Google Scholar]
  108. WuK. KwonS.H. ZhouX. FullerC. WangX. VadgamaJ. WuY. Overcoming challenges in small-molecule drug bioavailability: A review of key factors and approaches.Int. J. Mol. Sci.202425231312110.3390/ijms25231312139684832
     [Google Scholar]
  109. ShiY. LuA. WangX. BelhadjZ. WangJ. ZhangQ. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.Acta Pharm. Sin. B20211182396241510.1016/j.apsb.2021.05.00234522592
     [Google Scholar]
  110. LiT. ZhangH.Z. GeG.F. YueZ.R. WangR.Y. ZhangQ. GuY. SongM.J. LiW.B. MaM.Z. WangM.Z. YangH. LiY. LiH.Y. Albumin fusion at the N-Terminus or C-Terminus of HM-3 leads to improved pharmacokinetics and bioactivities.Biomedicines202199108410.3390/biomedicines909108434572270
     [Google Scholar]
  111. DengW. ZhaoZ. ZouT. KuangT. WangJ. Research advances in fusion protein-based drugs for diabetes treatment.Diabetes Metab. Syndr. Obes.20241734336210.2147/DMSO.S42152738288338
     [Google Scholar]
  112. BouneS. HuP. EpsteinA.L. KhawliL.A. Principles of N-linked glycosylation variations of IgG-based therapeutics: Pharmacokinetic and functional considerations.Antibodies2020922210.3390/antib902002232532067
     [Google Scholar]
  113. LiC. WangL.X. Chemoenzymatic methods for the synthesis of glycoproteins.Chem. Rev.2018118178359841310.1021/acs.chemrev.8b0023830141327
     [Google Scholar]
  114. ThompsonD.B. CronicanJ.J. LiuD.R. Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells.Methods in Enzymology.Elsevier2012293319
     [Google Scholar]
  115. SerflingR. CoinI. Incorporation of unnatural amino acids into proteins expressed in mammalian cells.Methods in Enzymology.Elsevier201689107
     [Google Scholar]
  116. BangaR.J. KroviS.A. NarayanS.P. SprangersA.J. LiuG. MirkinC.A. NguyenS.T. Drug-loaded polymeric spherical nucleic acids: Enhancing colloidal stability and cellular uptake of polymeric nanoparticles through DNA surface-functionalization.Biomacromolecules201718248348910.1021/acs.biomac.6b0156327931093
     [Google Scholar]
  117. RiccardiF. Dal BoM. MacorP. ToffoliG. A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy.Front. Pharmacol.202314127408810.3389/fphar.2023.127408837790810
     [Google Scholar]
  118. MareiH.E. CenciarelliC. HasanA. Potential of antibody–drug conjugates (ADCs) for cancer therapy.Cancer Cell Int.202222125510.1186/s12935‑022‑02679‑835964048
     [Google Scholar]
  119. ParslowA. ParakhS. LeeF.T. GanH. ScottA. Antibody–drug conjugates for cancer therapy.Biomedicines2016431410.3390/biomedicines403001428536381
     [Google Scholar]
  120. NhànN.T.T. YamadaT. YamadaK.H. Peptide-based agents for cancer treatment: Current applications and future directions.Int. J. Mol. Sci.202324161293110.3390/ijms24161293137629112
     [Google Scholar]
  121. SukJ.S. XuQ. KimN. HanesJ. EnsignL.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.Adv. Drug Deliv. Rev.201699Pt A285110.1016/j.addr.2015.09.01226456916
     [Google Scholar]
  122. SwierczewskaM. LeeK.C. LeeS. What is the future of PEGylated therapies?Expert Opin. Emerg. Drugs201520453153610.1517/14728214.2015.111325426583759
     [Google Scholar]
  123. LiC. LiT. TianX. AnW. WangZ. HanB. TaoH. WangJ. WangX. Research progress on the PEGylation of therapeutic proteins and peptides (TPPs).Front. Pharmacol.202415135362610.3389/fphar.2024.135362638523641
     [Google Scholar]
  124. KowalczykR. HarrisP.W.R. WilliamsG.M. YangS.H. BrimbleM.A. Peptide lipidation - A synthetic strategy to afford peptide based therapeutics.Adv. Exp. Med. Biol.2017103018522710.1007/978‑3‑319‑66095‑0_929081055
     [Google Scholar]
  125. Menacho-MelgarR. DeckerJ.S. HenniganJ.N. LynchM.D. A review of lipidation in the development of advanced protein and peptide therapeutics.J. Control. Release201929511210.1016/j.jconrel.2018.12.03230579981
     [Google Scholar]
  126. KapadiaC.H. MelamedJ.R. DayE.S. Spherical nucleic acid nanoparticles: Therapeutic potential.BioDrugs201832429730910.1007/s40259‑018‑0290‑529959665
     [Google Scholar]
  127. AmbroggioX.I. KuhlmanB. Computational design of a single amino acid sequence that can switch between two distinct protein folds.J. Am. Chem. Soc.200612841154116110.1021/ja054718w16433531
     [Google Scholar]
  128. RahbanM. AhmadF. PiatyszekM.A. HaertléT. SasoL. SabouryA.A. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry.RSC Advances20231351359473596310.1039/D3RA06476J38090079
     [Google Scholar]
  129. DingmanR. Balu-IyerS.V. Immunogenicity of protein pharmaceuticals.J. Pharm. Sci.201910851637165410.1016/j.xphs.2018.12.01430599169
     [Google Scholar]
  130. GronemeyerP. DitzR. StrubeJ. Trends in upstream and downstream process development for antibody manufacturing.Bioengineering20141418821210.3390/bioengineering104018828955024
     [Google Scholar]
  131. De JesusM. WurmF.M. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors.Comprehensive Biotechnology.Elsevier201139640110.1016/B978‑0‑444‑64046‑8.00199‑3
     [Google Scholar]
  132. HomayunB. LinX. ChoiH.J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals.Pharmaceutics201911312910.3390/pharmaceutics1103012930893852
     [Google Scholar]
  133. NiczeM. BorówkaM. DecA. NiemiecA. BułdakŁ. OkopieńB. The current and promising oral delivery methods for protein- and peptide-based drugs.Int. J. Mol. Sci.202425281510.3390/ijms2502081538255888
     [Google Scholar]
  134. LewisA.L. RichardJ. Challenges in the delivery of peptide drugs: An industry perspective.Ther. Deliv.20156214916310.4155/tde.14.11125690084
     [Google Scholar]
  135. NaeemM. ManzoorS. AbidM.U.H. TareenM.B.K. AsadM. MushtaqS. EhsanN. AmnaD. XuB. HazafaA. Fungal proteases as emerging biocatalysts to meet the current challenges and recent developments in biomedical therapies: An updated review.J. Fungi20228210910.3390/jof802010935205863
     [Google Scholar]
  136. NtanaF. MortensenU.H. SarazinC. FiggeR. Aspergillus: A powerful protein production platform.Catalysts2020109106410.3390/catal10091064
     [Google Scholar]
  137. SunY. QianY. ZhangJ. YaoC. WangY. LiuH. ZhongY. Development of a novel expression platform for heterologous protein production via deleting the p53-like regulator Vib1 in Trichoderma reesei.Enzyme Microb. Technol.202215510999310.1016/j.enzmictec.2022.10999335066395
     [Google Scholar]
  138. ChehelgerdiM. ChehelgerdiM. AllelaO.Q.B. PechoR.D.C. JayasankarN. RaoD.P. ThamaraikaniT. VasanthanM. ViktorP. LakshmaiyaN. SaadhM.J. AmajdA. Abo-ZaidM.A. Castillo-AcoboR.Y. IsmailA.H. AminA.H. Akhavan-SigariR. Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation.Mol. Cancer202322116910.1186/s12943‑023‑01865‑037814270
     [Google Scholar]
  139. NiaziS.K. MagoolaM. mRNA and synthesis-based therapeutic proteins: A non-recombinant affordable option.Biologics20233435537910.3390/biologics3040020
     [Google Scholar]
  140. MollaG. BitewM. Revolutionizing personalized medicine: Synergy with multi-omics data generation, main hurdles, and future perspectives.Biomedicines20241212275010.3390/biomedicines1212275039767657
     [Google Scholar]
  141. SuJ. YangL. SunZ. ZhanX. Personalized drug therapy: Innovative concept guided with proteoformics.Mol. Cell. Proteomics202423310073710.1016/j.mcpro.2024.10073738354979
     [Google Scholar]
  142. KohliA. VermaS. AgarwalN. KushwahaA. GuptaA. KumarA. ParikesitA.A. NaderiM. SinghA. KonnurR.G. MukherjeeS. Precision medicine in view of genomic biomarker discovery.Advances in medical technologies and clinical practiceIGI Global202418521610.4018/979‑8‑3693‑6597‑7.ch007
     [Google Scholar]
/content/journals/ppl/10.2174/0109298665387985250710041016
Loading
Recombinant Proteins: Evolution to their Therapeutic Potential
PPL 32, 557 (2025); https://doi.org/10.2174/0109298665387985250710041016
/content/journals/ppl/10.2174/0109298665387985250710041016
/content/journals/ppl/10.2174/0109298665387985250710041016
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer treatment; FDA-approved recombinant proteins; protein production systems; recombinant DNA technology; Recombinant proteins; therapeutic proteins

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test